The mRNA synthesis raw materials market size was valued at USD 1.70 billion in 2024 and is expected to reach USD 2.67 billion by 2032, growing at a CAGR of 5.81% over 2025-2032.
The mRNA synthesis raw materials market is growing fast, fueled by the explosive demand for mRNA-based treatments and vaccines, primarily in oncology, infectious diseases, and rare diseases. The success of mRNA COVID-19 vaccines has driven massive investment in mRNA platforms, so stimulating demand for high-purity raw materials, including IVT enzymes (T7 RNA polymerase and RNase inhibitors), nucleoside triphosphates (NTPs), capping reagents (CleanCap), and modified nucleotides (pseudouridine). Raw material requirements have led to a 5-to-10-fold rise above pre-pandemic levels. According to a survey conducted by BioProcess International (2024), more than 60% of mRNA developers experienced raw material supply issues in the last two years, revealing the imperative for strong sourcing strategies.
Apart from this, global investment in mRNA technology surpassed USD 5.5 billion in 2023, with industry giants including Moderna, BioNTech, and CureVac investing in manufacturing and R&D capacity. Moderna alone had its investment increased to USD 1.3 billion in 2023, with a significant focus on developing its pipeline of mRNA vaccines and therapies. Government support is also driving market growth. For instance, the U.S. Biomedical Advanced Research and Development Authority (BARDA) invested over USD 400 million in 2024 on advanced development of mRNA vaccines, driving upstream raw material demand.
Regulatory channels are also getting modified for the fast deployment of mRNA therapy. The U.S. FDA has also published revised CMC guidelines for mRNA treatments in 2024, particularly about low-endotoxin and GMP-compliant criteria-based approval for the suppliers of raw materials. Companies, including Thermo Fisher, have also concentrated on supply chain localization, investing in U.S. and European operations to produce locally.
Market Dynamics:
Drivers:
Rising Therapeutic Applications, R&D Expansion, and Regulatory Acceleration Fuel Market Growth
The expanding application of mRNA technology beyond vaccines into oncology, autoimmune disorders, and orphan genetic indications is propelling record demand for high-quality raw materials. As of 2024, there are more than 190 active global clinical trials in which mRNA therapeutics, including new indications, such as protein replacement therapies and CAR-T therapies, are utilized, which further require strict IVT-grade materials.
Investments are increasing too, and Sanofi has invested USD 2.2 billion through 2025 in building an in-house mRNA center focused on therapeutic R&D. CureVac and GSK's JV has invested over USD 856 million to build mRNA flu and oncology pipelines. The rising formulation complexity is also fueling demand for highly specialized reagents, such as modified nucleotides and high-efficiency capping analogs. Regulators are keeping pace, too. In mid-2024, detailed guidance on mRNA-based drug CMC requirements was released, which facilitates the faster scale-up for the providers of raw materials to GMP standards. These efforts are generating a sustained growth driver for the mRNA synthesis raw materials market, driven by the high-volume procurement agreements that are now standard in strategic pharma partnerships.
Restraints:
Supply Chain Vulnerabilities, Cost Pressure, and Quality Standardization Issues Hamper Market Expansion
One of the most significant restraints in the raw materials for mRNA synthesis market is the ongoing supply chain delays, particularly in the production of enzymes, capping reagents, and clean-room grade consumables. In a 2024 BioPlan Associates survey, 68% of mRNA developers experienced delays or shortages in acquiring high-purity reagent access, which affects batch release schedules. The stringent GMP-grade requirements and the endotoxin-free purity standards further reduce the qualified raw material supplier pool.
Additionally, the IVT reagent cost has increased by 30–40% over the last three years, with strict quality requirements and restrictive manufacturing scalability. The small biotech players are hit the hardest, with high upfront procurement costs restricting early-stage development. Another restraint is the absence of global standardization of raw material specifications, inducing batch-to-batch variability, which creates regulatory and reproducibility concerns. While large companies, such as Agilent and ST Pharm, are shifting toward end-to-end raw material pipeline integration, the industry still lacks harmonized reference standards. These collective constraints challenge the market in satisfying increasing demand at scale in line with affordability.
By Type
In 2024, the nucleotides segment accounted for the largest revenue share in the global mRNA synthesis raw materials market at 36.9% of total revenue. This is because nucleotides—ATP, GTP, CTP, and UTP- are essential to the in vitro transcription (IVT) process, which is the cornerstone of mRNA synthesis. Greater large-scale mRNA vaccine and therapeutic manufacturing has fueled demand for high-purity and GMP-grade nucleotides aggressively.
Alternatively, the capping agents segment is predicted to expand at the highest growth rate due to heightened emphasis on improving mRNA stability and translational efficiency. Advanced capping technologies, such as CleanCap analogs and anti-reverse cap analogs (ARCA), are increasing adoption for optimizing mRNA-based drug efficacy, especially in oncology and rare diseases.
By Application
The vaccine production segment retained the maximum revenue share of 82.3% in 2024, owing to global immunization drives and pandemic preparedness efforts. Bulk procurement of raw materials remains influenced by the high level of mRNA vaccines manufactured for COVID-19, RSV, and influenza.
The therapeutics production segment is growing at the maximum rate owing to a growing pipeline of mRNA-based therapeutics for cancer, cystic fibrosis, and genetic disease treatment. As increasing numbers of mRNA therapies move through clinical trials and into commercial development, the need for customized raw materials that are designed to therapeutic-grade specifications is growing at a fast pace.
By End Use
Pharmaceutical and biopharmaceutical companies dominated the end-use segment with a 48.5% market revenue contribution in 2024. They are attributed to their in-house large-scale production facility and investments by market leaders, such as Sanofi, BioNTech, and Moderna, in the development of the mRNA platform. They are utilizing large quantities of raw materials directly for the development of vaccines and therapies.
As biotech startups and mid-sized enterprises are outsourcing mRNA development on a significant scale to use the knowledge and infrastructure of CROs, the segment of Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) is expanding at the highest rate. Increasing partnerships and technology transfer agreements are further driving raw material demand from the segment.
North America was the biggest mRNA synthesis raw materials market in 2024, led by its established biotechnology infrastructure, high R&D spending, and presence of industry heavyweights, such as Moderna and Thermo Fisher Scientific.
The U.S. mRNA synthesis raw materials market size was valued at USD 0.57 billion in 2024 and is expected to reach USD 0.81 billion by 2032, growing at a CAGR of 4.62% over 2025-2032. The U.S. led the region, with the highest percentage, led by its enormous vaccine manufacturing capacity, continued research in RNA therapeutics, and government-private mRNA research worth over USD 3.2 billion since 2022. The region has streamlined FDA regulations, encouraging raw material standardization and expedited approvals. Canada is also advancing in-house mRNA manufacturing, such as initiatives including the Moderna vaccine factory in Quebec, with Mexico becoming a cost-effective hub for reagent manufacturing and research outsourcing.
Europe is the second-largest and fastest-expanding market, fueled by strong regulatory backing, world-class research institutions, and strategic collaborations. Germany dominates the regional market, spearheaded by BioNTech's high raw material usage and localization. Germany's government invested over €2 billion in biotech innovation during 2021–2024, fueling upstream demand. The U.K. is the region's fastest-expanding country, with government-backed initiatives to localize mRNA and vaccine manufacturing. The U.K. Vaccine Innovation Centre in Oxford fueled demand for cGMP-grade nucleotides and enzymes. France and Italy are expanding CDMO capacity to support regional therapeutic development.
Asia Pacific is the region's fastest-growing market, fueled by rising vaccine manufacturing capacity, expanding clinical trials, and encouraging government patronage for biotech localization. China leads the region by market share, with robust state backing for mRNA platforms and raw material self-sufficiency. Industry leaders, including Stemirna Therapeutics and Walvax Biotechnology, are scaling up local manufacturing with Chinese-made reagents. India is expanding most rapidly in Asia Pacific, with players including Biological E. and Gennova Biopharmaceuticals manufacturing mRNA vaccines and investing in local reagent production. Japan and South Korea are focusing on high-purity enzyme development and cleanroom reagent supply for precision therapeutics.
Leading mRNA synthesis raw materials companies in the market are Thermo Fisher Scientific, Merck KGaA, Cytiva, TriLink BioTechnologies, New England Biolabs, BioNTech, Moderna, CureVac, GenScript, and ST Pharm.
In January 2025, Thermo Fisher Scientific launched a new GMP-compliant IVT kit featuring ultra-pure nucleotide sets and RNase-free reagents designed to reduce purification time in mRNA manufacturing, enhancing scalability.
In April 2025, BioNTech announced a USD 1.07 billion expansion of its Marburg facility to include an in-house raw material production unit focused on high-volume synthesis of capping reagents and modified nucleotides, aiming to reduce reliance on third-party suppliers.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 1.70 billion |
| Market Size by 2032 | USD 2.67 billion |
| CAGR | CAGR of 5.81% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (Capping Agents (CleanCap Reagents, ARCA (Anti-Reverse Cap Analog), and Others), Nucleotides (Modified Nucleic Acids, (N1-methylpseudouridine-triphosphate, 5-Methylcytidine triphosphate (5mCTP), and Others), Natural Nucleic Acids (Adenine, Guanine, Cytosine, and Uracil), Plasmid DNA, Enzymes (Polymerase, RNase Inhibitor, DNase, and Others), Others) • By Application (Vaccine Production, Therapeutics Production, and Others) • By End Use (Biopharmaceutical & Pharmaceutical Companies, CROs & CMOs, and Academic & Research Institutes) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Thermo Fisher Scientific, Merck KGaA, Cytiva, TriLink BioTechnologies, New England Biolabs, BioNTech, Moderna, CureVac, GenScript, and ST Pharm |
Ans: The global mRNA synthesis raw materials market was valued at USD 1.70 billion in 2024 and is projected to reach USD 2.67 billion by 2032, growing at a CAGR of 5.81% from 2025 to 2032.
Ans: Growth is driven by the expanding application of mRNA technology in infectious disease vaccines, cancer therapeutics, and rare genetic disorders, along with heavy R&D investments, government funding, and the need for GMP-compliant raw materials such as nucleotides, capping agents, and enzymes.
Ans: Key players include Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), TriLink BioTechnologies, New England Biolabs, Cytiva (Danaher), BioNTech, Moderna, GenScript, CureVac, and ST Pharm.
Ans: North America, led by the U.S., dominates the market due to strong biotechnology infrastructure, government support, and major players headquartered in the region.
Ans: Future trends include the increased adoption of personalized mRNA therapies, a rise in self-amplifying and circular RNA research, and the development of next-gen capping technologies to improve mRNA stability and translation.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 R&D Investment Trends (2024)
5.2 mRNA Therapeutics/Platform Manufacturing Capacity, by Region (2024)
5.3 Spending on mRNA Raw Materials, by Source (Government, Biopharma, CDMOs), 2024
5.4 Pricing Trends of Key mRNA Raw Materials (2021–2024)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. mRNA Synthesis Raw Materials Market Segmentation by Type
7.1 Chapter Overview
7.2 Capping Agents
7.2.1 Capping Agents Market Trends Analysis (2021-2032)
7.2.2 Capping Agents Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.3 CleanCap Reagents
7.2.3.1 CleanCap Reagents Market Trends Analysis (2021-2032)
7.2.3.2 CleanCap Reagents Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.4 ARCA (Anti-Reverse Cap Analog)
7.2.4.1 ARCA (Anti-Reverse Cap Analog) Market Trends Analysis (2021-2032)
7.2.4.2 ARCA (Anti-Reverse Cap Analog) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.5 Others
7.2.5.1 Others Market Trends Analysis (2021-2032)
7.2.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Nucleotides
7.3.1 Nucleotides Market Trends Analysis (2021-2032)
7.3.2 Nucleotides Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.3 Modified Nucleic Acids
7.3.3.1 Modified Nucleic Acids Market Trends Analysis (2021-2032)
7.3.3.2 Modified Nucleic Acids Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.3.3 N1-methylpseudouridine-triphosphate
7.3.3.3.1 N1-methylpseudouridine-triphosphate Market Trends Analysis (2021-2032)
7.3.3.3.2 N1-methylpseudouridine-triphosphate Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.3.4 5-Methylcytidine triphosphate (5mCTP)
7.3.3.4.1 5-Methylcytidine triphosphate (5mCTP) Market Trends Analysis (2021-2032)
7.3.3.4.2 5-Methylcytidine triphosphate (5mCTP) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.3.5 Others
7.3.3.5.1 Others Market Trends Analysis (2021-2032)
7.3.3.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4 Natural Nucleic Acids
7.3.4.1 Natural Nucleic Acids Market Trends Analysis (2021-2032)
7.3.4.2 Natural Nucleic Acids Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4.3 Adenine
7.3.4.3.1 Adenine Market Trends Analysis (2021-2032)
7.3.4.3.2 Adenine Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4.4 Guanine
7.3.4.4.1 Guanine Market Trends Analysis (2021-2032)
7.3.4.4.2 Guanine Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4.5 Cytosine
7.3.4.5.1 Cytosine Market Trends Analysis (2021-2032)
7.3.4.5.2 Cytosine Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4.6 Uracil
7.3.4.6.1 Uracil Market Trends Analysis (2021-2032)
7.3.4.6.2 Uracil Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Plasmid DNA
7.4.1 Plasmid DNA Market Trends Analysis (2021-2032)
7.4.2 Plasmid DNA Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Enzymes
7.5.1 Enzymes Market Trends Analysis (2021-2032)
7.5.2 Enzymes Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5.3 Polymerase
7.5.3.1 Polymerase Market Trends Analysis (2021-2032)
7.5.3.2 Polymerase Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5.4 RNase Inhibitor
7.5.4.1 RNase Inhibitor Market Trends Analysis (2021-2032)
7.5.4.2 RNase Inhibitor Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5.5 DNase
7.5.5.1 DNase Market Trends Analysis (2021-2032)
7.5.5.2 DNase Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5.6 Others
7.5.6.1 Others Market Trends Analysis (2021-2032)
7.5.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Others
7.6.1 Others Market Trends Analysis (2021-2032)
7.6.2 Squamous Cell Carcinoma of the Head and Neck Market Size Estimates and Forecasts to 2032 (USD Billion)
8. mRNA Synthesis Raw Materials Market Segmentation By Application
8.1 Chapter Overview
8.2 Vaccine Production
8.2.1 Vaccine Production Market Trend Analysis (2021-2032)
8.2.2 Vaccine Production Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Therapeutics Production
8.3.1 Therapeutics Production Market Trends Analysis (2021-2032)
8.3.2 Therapeutics Production Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Others
8.4.1 Others Market Trends Analysis (2021-2032)
8.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. mRNA Synthesis Raw Materials Market Segmentation By End Use
9.1 Chapter Overview
9.2 Biopharmaceutical & Pharmaceutical Companies
9.2.1 Biopharmaceutical & Pharmaceutical Companies Market Trends Analysis (2021-2032)
9.2.2 Biopharmaceutical & Pharmaceutical Companies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 CROs & CMOs
9.3.1 CROs & CMOs Market Trends Analysis (2021-2032)
9.3.2 CROs & CMOs Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Academic & Research Institutes
9.4.1 Academic & Research Institutes Market Trends Analysis (2021-2032)
9.4.2 Academic & Research Institutes Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.2.3 North America mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.2.4 North America mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.2.5 North America mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.2.6.2 USA mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.2.6.3 USA mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.2.7.2 Canada mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.2.7.3 Canada mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.2.8.2 Mexico mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.2.8.3 Mexico mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.3 Europe
10.3.1 Trends Analysis
10.3.2 Europe mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.3 Europe mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.4 Europe mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.5 Europe mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.3.6 Germany
10.3.1.6.1 Germany mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.1.6.2 Germany mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.1.6.3 Germany mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.3.7 France
10.3.7.1 France mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.7.2 France mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.7.3 France mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.3.8 UK
10.3.8.1 UK mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.8.2 UK mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.8.3 UK mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.3.9 Italy
10.3.9.1 Italy mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.9.2 Italy mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.9.3 Italy mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.3.10 Spain
10.3.10.1 Spain mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.10.2 Spain mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.10.3 Spain mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.3.12 Poland
10.3.12.1 Poland mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.12.1 Poland mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.12.3 Poland mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.12.3 Poland mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.3.13 Turkey
10.3.13.1 Turkey mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.13.2 Turkey mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.13.3 Turkey mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.3.14 Rest of Europe
10.3.14.1 Rest of Europe mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.14.2 Rest of Europe mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.3.14.3 Rest of Europe mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.4 Asia-Pacific
10.4.1 Trends Analysis
10.4.2 Asia-Pacific mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.4.3 Asia-Pacific mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.4 Asia-Pacific mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.5 Asia-Pacific mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.4.6 China
10.4.6.1 China mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.6.2 China mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.6.3 China mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.4.7 India
10.4.7.1 India mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.7.2 India mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.7.3 India mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.8.2 Japan mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.8.3 Japan mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.9.2 South Korea mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.9.3 South Korea mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.4.10 Singapore
10.4.10.1 Singapore mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.10.2 Singapore mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.10.3 Singapore mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.4.11 Australia
10.4.11.1 Australia mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.11.2 Australia mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.11.3 Australia mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.4.12 Rest of Asia-Pacific
10.4.12.1 Rest of Asia-Pacific mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.12.2 Rest of Asia-Pacific mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.4.12.3 Rest of Asia-Pacific mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Trends Analysis
10.5.2 Middle East and Africa East mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.5.3 Middle East and Africa mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.4 Middle East and Africa mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.5.5 Middle East and Africa mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.5.6 UAE
10.5.6.1 UAE mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.6.2 UAE mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.5.6.3 UAE mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.5.7 Saudi Arabia
10.5.7.1 Saudi Arabia mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.7.2 Saudi Arabia mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.5.7.3 Saudi Arabia mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.5.8 Qatar
10.5.8.1 Qatar mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.8.2 Qatar mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.5.8.3 Qatar mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.5.9 South Africa
10.5.9 1 South Africa mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.9 2 South Africa mRNA Synthesis Raw Materials Market Estimates and Forecasts By Application (2021-2032) (USD Billion)
10.5.9 3 South Africa mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.5.10 Rest of Middle East & Africa
10.5.10.1 Rest of Middle East & Africa mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.10.2 Rest of Middle East & Africa mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.5.10.3 Rest of Middle East & Africa mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.6.3 Latin America mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.6.4 Latin America mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.6.5 Latin America mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.6.6.2 Brazil mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.6.6.3 Brazil mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.6.7.2 Argentina mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.6.7.3 Argentina mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America mRNA Synthesis Raw Materials Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.6.8.2 Rest of Latin America mRNA Synthesis Raw Materials Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10.6.8.3 Rest of Latin America mRNA Synthesis Raw Materials Market Estimates and Forecasts, By End Use (2021-2032) (USD Billion)
12. Company Profiles
12.1 Thermo Fisher Scientific
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 SWOT Analysis
12.2 Merck KGaA
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Products/ Services Offered
12.2.4 SWOT Analysis
12.3 Cytiva
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Products/ Services Offered
12.3.4 SWOT Analysis
12.4 TriLink BioTechnologies
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Products/ Services Offered
12.4.4 SWOT Analysis
12.5 New England Biolabs
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Products/ Services Offered
12.5.4 SWOT Analysis
12.6 BioNTech
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Products/ Services Offered
12.6.4 SWOT Analysis
12.7 Moderna
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Products/ Services Offered
12.7.4 SWOT Analysis
12.8 CureVac
12.8.1 Company Overview
12.8.2 Financial
12.8.3 Products/ Services Offered
12.8.4 SWOT Analysis
12.9 GenScript
12.9.1 Company Overview
12.9.2 Financial
12.9.3 Products/ Services Offered
12.9.4 SWOT Analysis
12.10 ST Pharm
12.10.1 Company Overview
12.10.2 Financial
12.10.3 Products/ Services Offered
12.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Type
Capping Agents
CleanCap Reagents
ARCA (Anti-Reverse Cap Analog)
Others
Nucleotides
Modified Nucleic Acids
N1-methylpseudouridine-triphosphate
5-Methylcytidine triphosphate (5mCTP)
Others
Natural Nucleic Acids
Adenine
Guanine
Cytosine
Uracil
Plasmid DNA
Enzymes
Polymerase
RNase Inhibitor
DNase
Others
Others
By Application
Vaccine Production
Therapeutics Production
Others
By End Use
Biopharmaceutical & Pharmaceutical Companies
CROs & CMOs
Academic & Research Institutes
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g., Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players